世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

欧州のDNAワクチン市場予測 2018-2026年

EUROPE DNA VACCINE MARKET FORECAST 2018-2026

 

出版社 出版年月電子版価格 ページ数
Inkwood Research
インクウッドリサーチ
2018年4月US$1,250
シングルユーザライセンス
85

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

サマリー

この調査レポートは欧州のDNAワクチン市場を分析・予測したInkwood Researchの市場調査報告書です。

Description

KEY FINDINGS
Europe DNA vaccine market is predicted to rise with a CAGR of 41.34%, increasing its revenue from $XX million to $XX million over the forecast period of 2018-2026.
MARKET INSIGHTS
The fact that these vaccines are increasingly being adopted for veterinary purposes and are highly useful for keeping in check the growing prevalence of diseases is significantly driving the market growth. Also, the third-generation vaccines have witnessed a rise in the number of investments in recent years, which is a very good news for the market. Still, there are factors like lengthy regulatory process and weak patent protection laws, coupled with the fact that the vaccines for humans are still under clinical trials, which are significantly holding back the market potential.
COMPETITIVE INSIGHTS
Some of the renowned players in the market are Vical Incorporated, Eurogentec S.A, Inovio Pharmaceuticals Inc, Sanofi, Madison Vaccines Incorporated (MVI), Astellas Pharma Inc, Merck & Co, Eli Lilly And Company, Glaxosmithkline Inc, Novartis Ag, and Xenetic Biosciences Inc.



目次

Table of Contents

1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
4. MARKET DETERMINANTS
4.1. DRIVERS
4.1.1. DNA VACCINES SHOW GREAT PROMISE IN CHECKING THE RISING PREVALENCE OF DISEASES
4.1.2. THIRD GENERATION VACCINATION IS SEEING A SURGE IN INVESTMENT
4.1.3. INCREASING ADOPTION OF DNA VACCINES FOR ANIMAL HEALTHCARE
4.2. RESTRAINTS
4.2.1. LENGTHY REGULATORY PROCESS
4.2.2. POOR PATENT PROTECTION IN SOME COUNTRIES
4.3. OPPORTUNITIES
4.3.1. TRANSFORMING HEALTHCARE LANDSCAPE
4.3.2. NEW DEVELOPMENTS IN BIOTECHNOLOGIES AND NANOTECHNOLOGIES
4.3.3. STABLE VACCINES MAKE IT ATTRACTIVE TO STORE AND TRANSPORT
4.4. CHALLENGES
4.4.1. VACCINES FOR HUMAN USAGE STILL UNDER CLINIC TRAIL PHASE
5. MARKET SEGMENTATION
5.1. MARKET BY TYPE 2018-2026
5.1.1. ANIMAL DNA VACCINE
5.1.2. HUMAN DNA VACCINE
5.2. MARKET BY APPLICATION 2018-2026
5.2.1. HUMAN DISEASE
5.2.2. VETERINARY DISEASE
5.3. MARKET BY TECHNOLOGY 2018-2026
5.3.1. PLASMID DNA VACCINES
5.3.2. PLASMID DNA DELIVERY
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCE MODEL
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREATS OF SUBSTITUTE PRODUCT
6.1.3. BARGAINING POWER OF BUYER
6.1.4. BARGAINING POWER OF SUPPLIER
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. KEY BUYING CRITERIA
6.2.1. EFFICACY
6.2.2. COST-EFFECTIVENESS
6.2.3. STABILITY
6.3. KEY MARKET PLAYERS
6.3.1. VICAL INCORPORATED
6.3.2. SANOFI
6.3.3. MERCK AND CORP
6.3.4. GSK
6.4. OPPORTUNITY MATRIX
6.5. VALUE CHAIN ANALYSIS
6.5.1. R&D
6.5.2. MANUFACTURING
6.5.3. RAW MATERIALS
6.5.4. MARKETING, DISTRIBUTION & END USER
6.6. LEGAL, POLICY AND REGULATORY FRAMEWORK
7. GEOGRAPHICAL ANALYSIS
7.1. EUROPE
7.1.1. UNITED KINGDOM
7.1.2. FRANCE
7.1.3. GERMANY
7.1.4. SPAIN
7.1.5. REST OF EUROPE
8. COMPETITIVE LANDSCAPE
8.1. STRATEGIC INITIATIVES
8.1.1. ACQUISITION
8.1.2. PARTNERSHIP
8.1.3. COLLABORATION
8.1.4. INNOVATION
8.1.5. DISINVESTMENT
8.1.6. EXPANSION
9. COMPANY PROFILE
9.1. MARKET SHARE
9.2. ASTELLAS PHARMA INC.
9.2.1. OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. SCOT ANALYSIS
9.2.4. STRATEGIC INITIATIVE
9.3. DENDREON CORPORATION (ACQUIRED BY SANPOWER GROUP)
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.3.4. STRATEGIC INITIATIVE
9.4. ELI LILLY AND COMPANY
9.4.1. OVERVIEW
9.4.2. PRODUCT PORTFOLIO
9.4.3. SCOT ANALYSIS
9.4.4. STRATEGIC INITIATIVE
9.5. EUROGENTEC S.A
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.5.4. STRATEGIC INITIATIVE
9.6. GLAXOSMITHKLINE INC.
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.6.4. STRATEGIC INITIATIVES
9.7. INOVIO PHARMACEUTICALS, INC.
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. SCOT ANALYSIS
9.7.4. STRATEGIC INITIATIVE
9.8. MADISON VACCINES INCORPORATED (MVI)
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. SCOT ANALYSIS
9.9. MERIAL LIMITED (ACQUIRED BY BOEHRINGER INGELHEIM)
9.9.1. OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. SCOT ANALYSIS
9.9.4. STRATEGIC INITIATIVE
9.10. MERCK & CO.
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. SCOT ANALYSIS
9.10.4. STRATEGIC INITIATIVE
9.11. NOVARTIS AG
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. SCOT ANALYSIS
9.11.4. STRATEGIC INITIATIVE
9.12. SANOFI
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. SCOT ANALYSIS
9.12.4. STRATEGIC INITIATIVE
9.13. VGXI
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. SCOT ANALYSIS
9.13.4. STRATEGIC INITIATIVES
9.14. VICAL INCORPORATED
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. SCOT ANALYSIS
9.14.4. STRATEGIC INITIATIVE
9.15. XENETIC BIOSCIENCES INC.
9.15.1. OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. SCOT ANALYSIS
9.15.4. STRATEGIC INITIATES
9.16. ZOETIS INC
9.16.1. OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. SCOT ANALYSIS
9.16.4. STRATEGIC INITIATES

?
TABLE LIST
TABLE 1 EUROPE DNA VACCINE MARKET 2018-2026 ($ MILLION)
TABLE 2 INTERVENTIONS AND PHASE OF CERTAIN DISEASE/CONDITIONS
TABLE 3 APPROACHES BEING TESTED TO ENHANCE THE LOW IMMUNOGENICITY
TABLE 4 CLINICAL TRIALS OF THE HUMANS INVOLVING DNA VACCINES
TABLE 5 TEMPERATURE REQUIREMENTS IN PRESERVATION FOR VARIOUS VACCINES
TABLE 6 EUROPE DNA VACCINE MARKET BY TYPE 2018-2026 ($ MILLION)
TABLE 7 EUROPE DNA VACCINE MARKET IN ANIMAL DNA VACCINE 2018-2026($MILLION)
TABLE 8 EUROPE DNA VACCINE MARKET IN HUMAN DNA VACCINE 2018-2026
TABLE 9 EUROPE DNA VACCINE MARKET BY APPLICATION 2018-2026 ($ MILLION)
TABLE 10 EUROPE DNA VACCINE MARKET IN HUMAN DISEASES APPLICATION 2018-2026 ($MILLION)
TABLE 11 EUROPE DNA VACCINE MARKET IN VETERINARY APPLICATION 2018-2026
TABLE 12 EUROPE DNA VACCINE MARKET BY TECHNOLOGY 2018-2026 ($ MILLION)
TABLE 13 EUROPE DNA VACCINE MARKET IN PLASMID DNA VACCINES TECHNOLOGY 2018-2026
TABLE 14 EUROPE DNA VACCINE MARKET IN PLASMID DNA DELIVERY TECHNOLOGY 2018-2026
TABLE 15 REGULATONS TO BE FOLLOWED BEFORE COMMERCIALIZATION

FIGURES LIST
FIGURE 1 EUROPE DNA VACCINE MARKET 2018-2026 ($ MILLION)
FIGURE 2 EUROPE DNA VACCINE MARKET IN VETERINARY DISEASES 2018-2026 ($ MILLION)
FIGURE 3 SHARE OF TRIALS BY VACCINE TARGET IN 2016
FIGURE 4 SEGMENT OF CLINICAL TRIALS OF DNA VACCINE BY CANCER MARKS IN 2016
FIGURE 5 CLINICAL TRIALS OF GENE THERAPHY
FIGURE 6 EUROPE DNA VACCINE MARKET SHARE BY TYPE 2017 & 2026 (%)
FIGURE 7 EUROPE DNA VACCINES MARKET IN ANIMAL DNA VACCINES 2018-2026 ($ MILLION)
FIGURE 8 EUROPE DNA VACCINE MARKET IN HUMAN DNA VACCINES 2018-2026($ MILLION)
FIGURE 9 EUROPE DNA VACCINE MARKET SHARE BY APPLICATION 2017 & 2026 (%)
FIGURE 10 EUROPE DNA VACCINES MARKET IN HUMAN DISEASES 2018-2026 ($ MILLION)
FIGURE 11 EUROPE DNA VACCINES MARKET IN VTERINARY APPLICATION 2018-2026 ($ MILLION)
FIGURE 12 EUROPE DNA VACCINES MARKET IN PLASMID DNA VACCINES TECHNOLOGY 2018-2026 ($ MILLION)
FIGURE 13 EUROPE DNA VACCINES MARKET IN PLASMID DNA DELIVERY TECHNOLOGY 2018-2026 ($ MILLION)
FIGURE 14 VALUE CHAIN ANALYSES FOR DNA VACCINE INDUSTRY
FIGURE 15 UNITED KINGDOM DNA VACCINE MARKET 2018-2026 ($ MILLION)
FIGURE 16 FRANCE DNA VACCINE MARKET 2018-2026 ($ MILLION)
FIGURE 17 GERMANY DNA VACCINE MARKET 2018-2026 ($ MILLION)
FIGURE 18 SPAIN DNA VACCINE MARKET 2018-2026 ($ MILLION)
FIGURE 19 REST OF EUROPE DNA VACCINE MARKET 2018-2026 ($ MILLION)
FIGURE 20 MARKET SHARES OF TOP FIVE COMPANIES FOR DNA VACCINES MARKET IN 2017

List of Tables

TABLE LIST
TABLE 1 EUROPE DNA VACCINE MARKET 2018-2026 ($ MILLION)
TABLE 2 INTERVENTIONS AND PHASE OF CERTAIN DISEASE/CONDITIONS
TABLE 3 APPROACHES BEING TESTED TO ENHANCE THE LOW IMMUNOGENICITY
TABLE 4 CLINICAL TRIALS OF THE HUMANS INVOLVING DNA VACCINES
TABLE 5 TEMPERATURE REQUIREMENTS IN PRESERVATION FOR VARIOUS VACCINES
TABLE 6 EUROPE DNA VACCINE MARKET BY TYPE 2018-2026 ($ MILLION)
TABLE 7 EUROPE DNA VACCINE MARKET IN ANIMAL DNA VACCINE 2018-2026($MILLION)
TABLE 8 EUROPE DNA VACCINE MARKET IN HUMAN DNA VACCINE 2018-2026
TABLE 9 EUROPE DNA VACCINE MARKET BY APPLICATION 2018-2026 ($ MILLION)
TABLE 10 EUROPE DNA VACCINE MARKET IN HUMAN DISEASES APPLICATION 2018-2026 ($MILLION)
TABLE 11 EUROPE DNA VACCINE MARKET IN VETERINARY APPLICATION 2018-2026
TABLE 12 EUROPE DNA VACCINE MARKET BY TECHNOLOGY 2018-2026 ($ MILLION)
TABLE 13 EUROPE DNA VACCINE MARKET IN PLASMID DNA VACCINES TECHNOLOGY 2018-2026
TABLE 14 EUROPE DNA VACCINE MARKET IN PLASMID DNA DELIVERY TECHNOLOGY 2018-2026
TABLE 15 REGULATONS TO BE FOLLOWED BEFORE COMMERCIALIZATION

Companies Mentioned

2. ASTELLAS PHARMA INC.
3. DENDREON CORPORATION (ACQUIRED BY SANPOWER GROUP)
4. ELI LILLY AND COMPANY
5. EUROGENTEC S.A
6. GLAXOSMITHKLINE INC.
7. INOVIO PHARMACEUTICALS, INC.
8. MADISON VACCINES INCORPORATED (MVI)
9. MERIAL LIMITED (ACQUIRED BY BOEHRINGER INGELHEIM)
10. MERCK & CO.
11. NOVARTIS AG
12. SANOFI
13. VGXI
14. VICAL INCORPORATED
15. XENETIC BIOSCIENCES INC.
16. ZOETIS INC

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る